Duckworth AD, et al. - In this fracture and bisphosphonates trial, researchers assessed the impacts of early bisphosphonate therapy on fracture healing and functional outcome after fracture of the distal radius. For this investigation, 421 bisphosphonate-naive patients were enlisted (aged ≥50 years) with a radiographically confirmed fracture of the distal radius and randomly allocated them 1:1 to receive alendronic acid 70 mg once weekly (n = 215) or placebo (n = 206) within 14 days of the fracture. According to findings, early administration of alendronic acid does not adversely affect fracture union or clinical outcome in these patients. If clinically indicated, bisphosphonate therapy can be started safely early after fracture.